EASi-HF™ Phase III trial in patients with HFpEF - Boehringer …
EASi-HF™ is the first clinical trial testing a novel selective aldosterone synthase inhibitor (ASi), vicadrostat, previously known as BI 690517, in people with heart failure and whose hearts can …
EASi-HF Trial | Chronic Heart Failure Clinical Research Trial …
The EASi-HF Trial is a clinical research trial looking at a potential new treatment option for people with chronic heart failure (HF) who have left ventricular ejection fraction (LVEF) of 40% or higher.
Purpose of Trial - Boehringer Ingelheim USA Medical and Clinical …
2025年3月6日 · EASi-HF - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral BI 690517 and Empagliflozin …
ClinicalTrials.gov
Glossary. Study record managers: refer to the Data Element Definitions if submitting registration or results information.. Search for terms
Breaking barriers in heart failure research | Boehringer Ingelheim
EASi-HF™ is the first clinical trial testing an aldosterone synthase inhibitor (ASi), vicadrostat, previously known as BI 690517, in people with heart failure and whose hearts can pump at …
UC Irvine Heart Failure Trial → Test Whether Vicadrostat in …
EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and …
Vicadrostat (BI 690517) + empagliflozin | Boehringer Ingelheim
Boehringer Ingelheim is developing vicadrostat (BI 690517), a novel selective and potent aldosterone synthase inhibitor (ASi) for people living with heart failure with preserved ejection …
EASi-HF Preserved - A Phase III Double-blind, Randomised, …
EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and …
EASi-HF - A Phase III Double-blind, Randomised, Parallel-group ...
EASi-HF - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral BI 690517 and Empagliflozin Compared With …
EASi-HF - 左室駆出率（LVEF）が40%以上の症候性心不全（HF…
EASi-HF - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral BI 690517 and Empagliflozin Compared With …
- 某些结果已被删除